HomeStock SectorsBioTechWhy Is Pelthos Therapeutics...

Why Is Pelthos Therapeutics Stock Trading Higher Thursday – Pelthos Therapeutics (AMEX:PTHS)

Pelthos Therapeutics Inc. PTHS on Thursday announced the launch of Zelsuvmi (berdazimer) topical gel 10.3% for molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.

Zelsuvmi received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, and caregivers to treat molluscum infections.

Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people, most of them children, with up to 6 million new incidents per year in the United States, the company said.

Also Read: Analyst Sees Big Upside In Ligand’s Capital-Efficient Biotech Strategy

Zelsuvmi is a topical nitric oxide-releasing gel for molluscum at diagnosis. The once-daily prescription medication is effective, well-tolerated, and convenient for at-home or on-the-go application.

It can be used to treat infections on the body, including sensitive areas such as the face, groin, or underarms.

Zelsuvmi was studied in the largest randomized clinical trial for the treatment of molluscum.

In the 891-patient phase 3 study:

  • Nearly 33% of patients saw complete clearance of molluscum lesions, compared with 19.7% of patients who did not receive the active ingredient at the twelfth week.
  • For many patients, Zelsuvmi demonstrated results within two weeks.

“We are launching our ZelsuvmiGo patient support program, which we expect to help onboard patients seamlessly and provide resources for caregivers,” said Sai Rangarao, Chief Commercial Officer at Pelthos.

“To ensure that Zelsuvmi reaches the people who need it quickly, we have hired 50 sales territory managers across the country to work with physicians who treat a high volume of patients with molluscum.”

In April, Ligand Pharmaceuticals Incorporated LGND and Channel Therapeutics Corporation CHRO agreed to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively Pelthos), with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel.

The merger was supported by $50 million in capital raised from a group of strategic investors led by Murchinson.

Under the merger agreement, Channel acquired 100% of Pelthos’ issued and outstanding equity interests, changed its name to Pelthos Therapeutics, and started trading on the NYSE American exchange under the ticker PTHS.

Price Action: PTHS stock traded higher by 7.65% to $17.74 premarket at last check Thursday.

Read Next:

Photo via Shutterstock

Most Popular

More from Author

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study – Pfizer (NYSE:PFE)

Pfizer Inc. PFE and Astellas Pharma Inc. ALPMF ALPMY on Thursday...

The Powell-Trump Clash is Set to Escalate

Growth challenges are mounting while tariffs will lift inflation, but stagflation...

Why Is AbbVie Stock Trading Higher On Thursday? – AstraZeneca (NASDAQ:AZN), AbbVie (NYSE:ABBV)

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos...

Dynamic Hedging and FX Risk Analysis Within Tactical Asset Allocation Rules

Often, investors fully hedge their portfolios for currency risk. This can...

Read Now

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study – Pfizer (NYSE:PFE)

Pfizer Inc. PFE and Astellas Pharma Inc. ALPMF ALPMY on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence...

The Powell-Trump Clash is Set to Escalate

Growth challenges are mounting while tariffs will lift inflation, but stagflation fears are wide of the mark. The Fed will likely delay rate cuts until the end of the year, despite escalating pressure from the president, but may move in larger steps when it does cutConsumer Caution...

Why Is AbbVie Stock Trading Higher On Thursday? – AstraZeneca (NASDAQ:AZN), AbbVie (NYSE:ABBV)

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.“Multispecifics including trispecific antibodies represent...

Dynamic Hedging and FX Risk Analysis Within Tactical Asset Allocation Rules

Often, investors fully hedge their portfolios for currency risk. This can lead to significant drag in performance for currencies with negative carry. However, not hedging the foreign currency exposure can lead to significant drawdowns, especially for conservative investments. In this paper, we consider a conservative, global tactical...

German CPI Confirmed at 2.0%, Euro Drifting, FOMC Split Over Cuts

The euro continues to have a quiet week and is drifting for a third consecutive day. In the European session, is trading at 1.1730, up 0.09% on the day.German Inflation Dips to 2% as food, Energy Prices FallGerman inflation rose 2.0% y/y in June, in line...

Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble? – Klotho Neurosciences (NASDAQ:KLTO)

Shares of Klotho Neurosciences, Inc. KLTO have soared more than 1000% over the past three months on promising results and breakthrough hopes. Klotho stock was in the spotlight again Thursday after announcing an FDA nod on its ALS treatment candidate. What's Driving The Rally: Klotho announced it has received...

Eurozone Economic Weakness Laid Bare as US Front-Loading Effects Wane

Eurozone data remains volatile amid trade war developments, but the underlying trend is still sluggish. Uncertainty is slowing domestic demand, which contributes to our expectation of a further rate cut from the European Central Bank in SeptemberEurozone Economy Shows Further Weakness in the Second QuarterThe eurozone economy...

SeaStar Medical’s QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka – Johnson & Johnson...

When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern. That's particularly true regarding pediatric AKI – each year, about 4,000 children with AKI require continuous renal replacement therapy (RRT), with a mortality rate of approximately 51-58%. Many of those...

Why Are Biotech Stocks Ultragenyx And Mereo Facing A Sell-Off? – Ultragenyx Pharmaceutical (NASDAQ:RARE), Mereo BioPharma Group (NASDAQ:MREO)

Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday.What Happened?The companies on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward...

3 Things to Watch This Week: Trade-War Worries, Earnings, and Record Highs

After the long holiday weekend, we’re back to a full week of trading. Here are a few things we’re watching for this week. First, trade-war headlines. The Trump Administration’s original deadline was July 9th, and while that date is still in focus for investors, it now appears that many...

The Energy Report: Peak Oil Demand

Just breaking… is discussing pausing their output production hikes from October, saying that we would not ever consume as much oil as we did in the past. As predicted the “Peak Demand” oil theory has been dis-proven again. The United Arab Emirates oil minister Suhail Al Mazroui said that...

FTSE 100, DAX Forecast: 2 Top Trades to Watch

rises to record highs, boosted by miners. hits record highs as investors await EU-US trade deal news.FTSE Rises to Record Highs, Boosted by MinersThe FTSE 100 has risen to a record high, boosted by the mining sector, as investors react to Trump’s latest tariff announcement. Anglo...